Enhancement of radiation effects by combined docetaxel and carboplatin treatment in vitro

Radiation Oncology Investigations

Volumn 7, Issue 6, 1999, Pages 343-352

  Amorino, George P ^a,b   Hamilton, Virginia M ^a   Choy, Hak ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY   (United States)

Author keywords

Carboplatin; Docetaxel; Lung cancer; Paclitaxel; Radiotherapy

Indexed keywords

CARBOPLATIN; DOCETAXEL; PACLITAXEL;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CARCINOMA CELL; CELL CYCLE; COLONY FORMING UNIT; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; HUMAN; HUMAN CELL; LARGE CELL CARCINOMA; LUNG CARCINOMA; PRIORITY JOURNAL; RADIATION DOSE; RADIATION RESPONSE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOSE-RESPONSE RELATIONSHIP, RADIATION; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; FLOW CYTOMETRY; HUMANS; LUNG NEOPLASMS; PACLITAXEL; RADIATION DOSAGE; RADIATION-SENSITIZING AGENTS; RADIOTHERAPY, ADJUVANT; TAXOIDS; TUMOR CELLS, CULTURED;

EID: 0033378780     PISSN: 10657541     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1520-6823(1999)7:6<343::AID-ROI4>3.0.CO;2-C     Document Type: Article

References (42)

1. Choy H, Akerley W, Safran H, Graziano S, Chung C, Williams T, Cole B, Kennedy T. Multi-Institutional Phase II Trial of Paclitaxel, Carboplatin, and Concurrent Radiation Therapy for Locally Advanced NSCLC. J Clin Oncol 1998;16(10):3316-3322.
2. Bonomi P, Siddiqui S, Lincoln S, Sharma M, Recine D, Warren W, Faber LP Escalating paclitaxel doses combined with carboplatin/etoposide and thoracic radiotherapy as preoperative or definitive treatment for stage III nonsmall-cell lung cancer. Semin Oncol 1996;23 (6 Suppl 16):102-107.
3. Aisner J, Hiponia D, Conley B, Jacobs M, Gray W, Belani CP. Combined modalities in the treatment of head and neck cancers. Semin Oncol 1995;23(3 Suppl 6):28-34.
4. Langer CJ, Movsas B, Hudes R, Schol J, Keenan E, Kilpatrick D, Yeung C, Curran W. Induction paclitaxel and carboplatin followed by concurrent chemoradiotherapy in patients with unresectable, locally advanced nonsmall-cell lung carcinoma: report of Fox Chase Center study 94-001. Semin Oncol 1997;24(4 Suppl 12):S12-89-S12-95.
5. rd, Hande KR, Porter LL, Rosenblatt P, Yunus F, Schlabach L, Smith C, Shyr Y, LaPorte K, Johnson DH. Preliminary analysis of a phase II study of paclitaxel, carboplatin, and hyperfractionated radiation therapy for locally advanced inoperable nonsmall-cell lung cancer. Semin Oncol 1997; 24(4 Suppl 12):S12-21-S12-26.
6. Socinski MA, Clark JA, Halle J, Steagall A, Kaluzny B, Rosenman JG. Induction therapy with carboplatin/ paclitaxel followed by concurrent carboplatin/ paclitaxel and dose-escalating conformal radiotherapy in the treatment of locally advanced, unresectable non-small cell lung cancer: preliminary report of a phase I trial. Semin Oncol 1997;24(4 Suppl 12):S12-117-S12-122.
7. Conley B, Jacobs M, Suntharalingam M, Zacharski D, Ord RA, Gray W, Aisner J. A pilot trial of paclitaxel, carboplatin, and concurrent radiotherapy for unresectable squamous cell carcinoma of the head and neck. Semin Oncol 1997;24(1 Suppl 2):S2-78-S2-80.
8. Chougule P, Wanebo H, Akerley W, McRae R, Nigri P, Leone L, Safran H, Ready N, Koness RJ, Radie-Keane K, Cole B. Concurrent paclitaxel, carboplatin, and radiotherapy in advanced head and neck cancers: a phase II study-preliminary results. Semin Oncol 1997;24(6 Suppl 19):S19-57-S19-61.
9. Levasseur LM, Greco WR, Rustum YM, Slocum HK. Combined action of paclitaxel and cisplatin against wildtype and resistant human ovarian carcinoma cells. Cancer Chemother Pharmacol 1997;40(6):495-505.
10. Mohith A, Photiou A, Retsas S. The combination of paclitaxel with cisplatin exhibits antagonism in vitro against human melanoma. Anti-Cancer Drugs 1996; 7(4):493-498.
11. Kano Y, Akutsu M, Tsunoda S, Suzuki K, Yazawa Y. In vitro schedule-dependent interaction between paclitaxel and cisplatin in human carcinoma cells. Cancer Chemother Pharmacol 1996;37(6):525-530.
12. Vanhoefer U, Harstrick A, Wilke H, Schleucher N, Walles H, Schroder J, Seeber S. Schedule-dependent antagonism of paclitaxel and cisplatin in human gastric and ovarian cell lines in vitro. Eur J Cancer 1995; 31A(1):92-97.
13. Liebmann JE, Fisher J, Teague D, Cook JA. Sequence dependence of paclitaxel (Taxol) combined with cisplatin or alkylators in human cancer cells. Oncol Res 1994;6(1):25-31.
14. Untch M, Sevin BU, Perras JP, Angioli R, Untch A, Hightower RD, Koechli O, Averette HE. Evaluation of paclitaxel (taxol), cisplatin, and the combination paclitaxel-cisplatin in ovarian cancer in vitro with the ATP cell viability assay. Gynecol Oncol 1994;53(1):44-49.
15. Clark JW, Santos-Moore AS, Choy H. Sequencing of Taxol and Carboplatinum therapy. Proceedings of the American Association for Cancer Research 1995;36: 298.
16. Schiff PB, Fant J, Horowitz SB. Promotion of microtubule assembly in vitro by taxol. Nature 1979; 277(5698):665-667.
17. DeBrabander M, Geuens G, Nuydens R, Willebrords R, DeMey J. Taxol induces the assembly of free microtubules in living cells and blocks the organizing capacity of the centrosomes and kinetochores. Proc Natl Acad Sci USA 1981;78(9):5608-5612.
18. Terasima R, Tolmach LJ. X-ray sensitivity and DNA synthesis in synchronous populations of HeLa cells. Science 1963;140:490-492.
19. Sinclair WK, Morton RA. X-ray sensitivity during the cell generation cycle of cultured Chinese hamster cells. Radiat Res 1966;29:450-474.
20. Choy H, Rodriquez FF, Koester S, Hilsenbeck S, Von Hoff DD. Investigation of taxol as a potential radiation sensitizer. Cancer 1993;71(11):3774-3778.
21. Liebmann J, Cook JA, Fisher J, Teague D, Mitchell JB. In vitro studies of Taxol as a radiation sensitizer in human tumor cells. J. Natl Cancer Inst 1994;86(6): 441-446.
22. Hennequin C, Giocanti N, Favaudon V Interaction of ionizing radiation with paclitaxel (Taxol) and docetaxel (Taxotere) in HeLa and SQ20B cells. Cancer Res 1996; 56:1842-1850.
23. Cividalli A, Arcangeli G, Cruciani G, Lividi E, Cordelli E, Danesi DT. Enhancement of radiation response by paclitaxel in mice according to different treatment schedules. Int J Radiat Oncol Biol Phys 1998;40(5): 1163-1170.
24. Milas L, Hunter NR, Mason KA, Kurdorglu B, Peters LJ Enhancement of tumor radioresponse of a murine mammary carcinoma by paclitaxel. Cancer Res 1994; 54(13):3506-3510.
25. Mellish KJ, Barnard CF, Murrer BA, Kelland LR. DNA-binding properties of novel cis- and trans platinum-based anticancer agents in 2 ovarian carcinoma cell lines. Int J Cancer 1995;62(6):717-723.
26. Knox RJ, Friedlos F, Lydall DA, Roberts JJ. Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA. Cancer Res 1986;46(4 Pt 2):1972-1979.
27. Coughlin CT, Richmond RC. Biologic and clinical developments of cisplatin combined with radiation: concepts, utility, projections for new trials, and the emergence of carboplatin. Semin Oncol 1989;16(4 Suppl 6): 31-43.
28. Begg AC, van der Kolk PJ, Emondt J, Bartelink H. Radiosensitization in vitro by cis-diammine (1,1-cyclobuanedicarboxylato) platinum(II) (carboplatin, JM8) and ethylenediammine-malonatoplatinum(II) (JM40). Radiother Oncol 1987;9:157-165.
29. Yang L, Douple EB, O'Hara JA, Wang H. Production of DNA double-strand breaks by interactions between carboplatin and radiation: a potential mechanism for radiopotentiation. Radiat Res 1995;143: 309-315.
30. Groen HJM, Sleijfer S, Meijer C, Kampinga HH, Konings AWT, De Vries EGE, Mulder NH. Carboplatin-and cisplatin-induced potentiation of moderate-dose radiation cytotoxicity in human lung cancer cell lines. Br J Cancer 1995;72(6):1406-1411.
31. Sinclair WK, Morton RA. X-ray and ultraviolet sensitivity of synchronized Chinese hamster cells at various stages of the cell cycle. Biophys J 1965;5:1-12.
32. Elkind MM, Whitmore GF. The radiobiology of cultured mammalian cells. New York: Gordon and Breach; 1967, p. 20-26.
33. Schwachofer JH, Crooijmans RP, Hoogenhout J, Kal HB, Theeuwes AG. Effectiveness in inhibition of recovery of cell survival by cisplatin and carboplatin: influence of treatment sequence. Int J Radiat Oncol Biol Phys 1991;20(6):1235-1241.
34. Gorczyca W, Gong J, Ardelt B, Traganos F, Darzynkiewicz Z. The cell cycle related differences in susceptibility of HL-60 cells to apoptosis induced by various antitumor agents. Cancer Res 1993;53(13):3186-3192.
35. Sigdestad CP, Grdina DJ. In vivo cell cycle phase-preferential killing of murine fibrosarcoma cells by cisplatin. Cancer Treat Rep 1981;65(9-10):845-851.
36. Millross CG, Peters LJ, Hunter NR, Mason KA, Milas L. Sequence-dependent antitumor activity of paclitaxel (taxol) and cisplatin in vivo. Int J Cancer 1995;62(5): 599-604.
37. Rowinsky EK, Citardi MJ, Noe DA, Donehower RC. Sequence-dependent cytotoxic effects due to combinations of cisplatin and the antimicrotubule agents taxol and vincristine. J Cancer Res Clin Oncol 1993; 119(12):727-733.
38. Ma J., Verweij J, Planting AS, Kolker HJ, Loos WJ, de Boer-Dennert M, van der Burg ME, Stoter G, Schellens JH. Docetaxel and paclitaxel inhibit DNA-adduct formation and intracellular accumulation of cisplatin in human leukocytes. Cancer Chemother Pharmacol 1996; 37(4):382-384.
39. Liebmann J, Cook JA, Fisher J, Teague D, Mitchell JB. Changes in radiation survival curve parameters in human tumor and rodent cells exposed to paclitaxel (Taxol). Int J Radiat Oncol Biol Phys 1994;29(3):559-564.
40. Karantanis E, Nicholson S, Morris DL. Taxotere inhibits in vitro growth of human colonic cancer cell lines. Eur J Surg Oncol 1994;20(6):653-657.
41. Paoletti A, Giocanti N, Favaudon V, Bornens M. Pulse treatment of interphasic HeLa cells with nanomolar doses of docetaxel affects centrosome organization and leads to catastrophic exit of mitosis. J Cell Sci 1997; 110(Pt 19):2403-2415.
42. Hennequin C, Giocanti N, Favaudon V. S-phase specificity of cell killing by docetaxel (Taxotere) in synchronized HeLa cells. Br J Cancer 1995;71(6):1194-1198.